Circulating microRNA signatures in mice exposed to lipoteichoic acid
- Ching-Hua Hsieh†1,
- Johnson Chia-Shen Yang†1,
- Jonathan Chris Jeng2,
- Yi-Chun Chen1,
- Tsu-Hsiang Lu1,
- Siou-Ling Tzeng1,
- Yi-Chan Wu1,
- Chia-Jung Wu1 and
- Cheng-Shyuan Rau3Email author
© Hsieh et al.; licensee BioMed Central Ltd. 2013
Received: 22 October 2012
Accepted: 30 December 2012
Published: 4 January 2013
Previously, we had identified a specific whole blood–derived microRNAs (miRNAs) signature in mice following in vivo injection of lipopolysaccharide (LPS) originated from Gram-negative bacteria. This study was designed to profile the circulating miRNAs expression in mice exposed to lipoteichoic acid (LTA) which is a major component of the wall of Gram-positive bacteria.
C57BL/6 mice received intraperitoneal injections of 100 μg of LTA originated from Bacillus subtilis, Streptococcus faecalis, and Staphylococcus aureus were killed 6 h and the whole blood samples were obtained for miRNA expression analysis using a miRNA array (Phalanx miRNA OneArray® 1.0). Up-regulated expression of miRNA targets in the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2−/− mice upon LTA treatment in 10, 100, or 1000 ug concentrations was quantified at indicated time (2, 6, 24, and 72 h) using real-time RT-PCR and compared with that in the serum of C57BL/6 mice injected with 100 ug of LPS. A significant increase of 4 miRNAs (miR-451, miR-668, miR-1902, and miR-1904) was observed in the whole blood and the serum in a dose- and time-dependent fashion following LTA injection. Induction of miRNA occurred in the serum after 2 h and persisted for at least 6 h. No increased expression of these 4 miRNAs was found in the WBCs. Higher but not significant expression level of these 4 miRNAs were observed following LTA treatment in the serum of Tlr2−/−against that of C57BL6 mice. In contrast, LPS exposure induced moderate expression of miR-451 but not of the other 3 miRNA targets.
We identified a specific circulating miRNA signature in mice exposed to LTA. That expression profile is different from those of mice exposed to LPS. Those circulating miRNAs induced by LTA or LPS treatment may serve as promising biomarkers for the differentiation between exposures to Gram-positive or Gram-negative bacteria.
KeywordsMicroRNAs Lipoteichoic acid Lipopolysaccharide Toll-like receptor Gram-positive bacteria Gram-negative bacteria Microarray
MicroRNAs (miRNAs) are small non-coding, endogenous, single-stranded RNA molecules that regulate the activity of specific mRNA targets and play important roles in a wide range of physiologic and pathologic processes [1, 2]. Alteration of miRNA expression profiles has been observed in various diseases and help distinguish between disease states . Identification of these multiple miRNA changes is valuable because specific signatures of miRNA combinations unique to a normal physiological or pathological state can serve as an useful reference . Recently, biochemical analyses indicate that miRNAs are resistant to RNase activity, extreme pH and temperature, extended storage, and large numbers of free-thaw cycles [5, 6]. In addition, extracellular miRNAs circulate in the blood are remarkably stable , albeit there is presence of ribonuclease in both plasma and serum [8, 9]. With the possibility to analyze multiple miRNAs in parallel to increase sensitivity and specificity by using complex miRNA expression patterns, miRNAs might constitute very useful and accessible diagnostic tools in a cluster pattern [5, 10].
Early diagnosis of bacterial infection is critical for preventing further complications. Pathological processes after bacterial infection are mainly induced by structural components of bacterial cell walls ; In Gram-negative bacteria, these components are lipopolysaccharide (LPS)  and in Gram-positive flora, these components are represented by lipoteichoic acid (LTA) . The appearance of LPS and LTA in the blood leads to activation of multiple intracellular signaling pathways necessary for the rapid change of the target cell functional state to provide an efficient innate immune response depends on Toll-like receptor 4 (TLR4) and Toll-like receptor 2 (TLR2), respectively. Previously, we had identified a specific whole blood–derived miRNA signature in mice exposed to LPS as there was a dose- and time-dependent upregulated expression of the miRNA targets (let-7d, miR-15b, miR-16, miR-25, miR-92a, miR-103, miR-107 and miR-451) follo-wing in vivo LPS injection . The above-mentioned 8 miRNAs was evident as early as 2 h and persisted for at least 6 h following injection with 100 ug of LPS. In contrast, LTA exposure induced moderate expression of miR-451 but not of the other 7 miRNA targets .
Seeing these circulating miRNAs may serve as promising biomarkers for the differentiation between in vivo exposure to LPS or LTA. The present study was designed to profile the circulating miRNA expression exposure to LTA in mice.
C57BL/6 mice were purchased from BioLasco (Taiwan). Tlr2−/− (B6.129-Tlr2tm1Kir/J) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All housing conditions were established and surgical procedures, analgesia, and assessments were performed in an AAALAC-accredited, SPF facility following national and institutional guidelines. Animal protocols were approved by the IACUC of Chang Gung Memorial Hospital. LTA from different Gram-positive bacteria, including Bacillus subtilis (catalog no. L3265), Streptococcus faecalis (L4015), and Staphylococcus aureus (L2515) as well as LPS from different Gram-negative bacteria, including Escherichia coli serotype 026:B6 (L3755), Klebsiella pneumonia (L1519), Salmonella enterica serotype Enteritidis (L6761), Serratia marcescens (L6136), and Pseudomonas aeruginosa (L9143) were purchased from Sigma (St. Louis, MO, USA). When the mice gained a weight of 20–35 g and became 4–6 weeks old, they were intraperitoneally injected with 10, 100, 1000 μg of LTA reconstituted in 100 μL of phosphate-buffered saline (PBS). Animals were sacrificed at 2, 6, 24, and 72 h after LPS injection. The control group was injected with 100 μL PBS. Whole blood was drawn for miRNA expression analysis. For comparison, intraperitoneal injections of 10, 100, 1000 μg of LPS from Escherichia coli serotype 026:B6 (L3755) were performed in C57BL/6 mice, that were killed 6 h after injection and the whole blood was obtained for quantification of miRNA expression.
RNA isolation and preparation
In brief, coagulated whole blood samples (1 mL per mouse) were collected at indicated times of experiment. After incubating the whole blood at 37°C for 1 h and centrifugating at 3,000 rpm for 10 min, the white blood cells (WBCs) were slowly removed from the corresponding layers and the serum was extracted and stored at −80°C before use. Total RNA was extracted from whole blood, serum and WBCs by using the RNeasy Mini kit (Qiagen, Hilden, Germany). Purified RNA was quantified by measuring the absorbance at 260 nm by using an SSP-3000 Nanodrop spectrophotometer (Infinigen Biotechnology, Inc., City of Industry, CA, USA). For miRNA array analyses, the quality of purified RNA was assessed using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). Total RNA (2 μg) was reverse transcribed into cDNA by using the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Target miRNA was reverse transcribed using sequence-specific stem-loop primers. miRNA cDNA (10 ng) for each target was used for real-time PCR.
miRNA microarray analysis
Mouse genome-wide miRNA microarray analysis was performed by Phalanx Biotech with the Mouse & Rat miRNA OneArray® 1.0 (Phalanx Biotech Group, Hsinchu, Taiwan) contains a total of 2,319 probes, including 135 experimental control probes and 728 unique miRNA probes from mouse and 348 from rat (miRBase Release 12.0). Briefly, fluorescent targets were prepared from 2.5-μg total RNA samples by using the miRNA ULS™ Labeling Kit (Kreatech Diagnostics, Amsterdam, Netherlands). Labeled miRNA targets enriched using NanoSep 100K (Pall Corporation, Port Washington, NY, USA) were hybridized to the microarray with Phalanx hybridization buffer by using the OneArray® Hybridization Chamber. After overnight hybridization at 37°C, non-specific binding targets were by 3 washing steps (Wash I: 37°C, 5 min; Wash II: 37°C, 5 min and 25°C, 5 min; and Wash III: rinse 20 times). The slides were dried by centrifugation and scanned using Axon 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). The Cy5 fluorescent intensities of each spot were analyzed using GenePix 4.1 software (Molecular Devices). The signal intensity of each spot was processed using the R program. We filtered out spots for which the flag was <0. Spots that passed the criteria were normalized using the 75% scaling normalization method. Normalized spot intensities were converted into gene expression log2 ratios for the control and treatment groups. Spots with log2 ratios ≥ 1 or log2 ratio ≤ −1 and P-value < 0.05 are analyzed further. These differentially expressed miRNAs were subjected to hierarchical cluster analysis using average linkage and Pearson correlation as a measure of similarity. The GEO accession number for the microarray data is GSE41837.
Quantification of miRNA expression
The miRNA expression of the whole blood, serum and WBCs was quantified by real-time RT-PCR using Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems) to verify the miRNA targets with up-regulated expression that were detected through the miRNA array from whole blood following injection of LTA different doses (10, 100, and 1000 μg) or at indicated survival times (2, 6, 24, and 72 h). Expression of the miRNAs in serum following intraperitoneal injections of LPS at doses of 10, 100, and 1000 μg were measured for comparison. Expression of each miRNA of the whole blood samples or WBCs was represented relative to the expression of U6 small nuclear RNA (U6 snRNA) as an internal control. For the serum, 25 fmol of single stranded cel-miR-39 synthesized by Invitrogen (Carlsbad, CA 92008) were spiked into 400 μL of serum an internal control for the expression of each miRNA. We calculated the fold-expression of induction as the relative expression value obtained from 6 samples in comparison with that from the control group. Intergroup group comparisons were performed using analysis of variance (ANOVA) and an appropriate post hoc test to compensate for multiple comparisons (SigmaStat; Jandel, San Rafael, CA, USA). P-values < 0.05 were considered significant.
Up-regulated miRNA targets in microarray analysis
Up-regulated miRNA targets more than double of those from the controls in microarray analysis of the whole blood of experimental mice at 6 h after the injection of 100 μg of LTA from Bacillus subtilis , Streptococcus faecalis , and Staphylococcus aureus (n=3 for each subgroup)
LTA induced miRNA targets
Expression profiles of miRNAs
miRNA expression in the serum and WBCs in C57BL/6 and Tlr2 knockout mice
miRNA expression after LPS injection
While LPS and LTA induce similar inflammatory responses, the signaling and sensing of LPS and LTA differ significantly. In previous study, we had demonstrated that expression of multiple miRNAs (let-7d, miR-15b, miR-16, miR-25, miR-92a, miR-103, miR-107, and miR-451) is significantly altered in the whole blood of mice after exposure to LPS in a dose- and time-dependent fashion . Besides, LTA did not up-regulate the expression of these miRNA targets, except miR-451, in the concentration up to 1000 ug . In this study, we demonstrated that expression of miR-451, miR-668, miR-1902, and miR-1904 is significantly altered in the whole blood and serum of mice after exposure to LTA in a dose- and time-dependent fashion. Additionally, LPS significantly induced miR-451 expression at concentrations of 10, 100 and 1000 μg but not increase the expression of the other 3 miRNA targets. Therefore, a specific signature of miRNAs in the circulation of mice exposed to LPS and LTA may serve as promising as biomarkers for their exposure.
Among these 4 miRNA targets, miR-451 had been reported to be a promising biomarker for microRNAs involved in lung tissue infected with pathogen as Actinobacillus pleuropneumoniae. miR-451 had also been found to direct a negative regulatory cascade to tune the cytokine production of dendritic cells including IL-6, TNF, CCL5/RANTES, and CCL3/MIP1α . However, miR-451 also presents with a significant level in RBCs and comprised the major source of variation in its level measured in the circulation and deterred its use as a circulating biomarker . Up-regulation miR-668 in the peripheral blood of mice exposed to mainstream smoking had been found to reflect the dynamic pathological changes in smoking-related interstitial fibrosis , but so far there was no linkage of miR-668 to any infectious disease had been reported in the literature. Notably, miR-451 was both induced by LPS and LTA treatment in this study and the expression of miR-668 was significantly induced in the whole blood and in the serum by the high dose of LTA in 1000 ug concentration, but not by lower to medium dose of LTA in 10 and 100 ug concentrations. Therefore, the use of miR-451 or miR-668 as a biomarker to differentiate the exposure to LPS or LTA is not suitable. In addition, expression signature of miR-1902 and miR-1904 may be useful in differentiating infections caused by gram-positive bacteria to those by gram-negative bacteria. In the mouse jejunum infections with Eimeria papillata, miR-1902 expression was able to serve as one of those biomarkers to reflect the garlic treatment of this illness . A study on mouse-adapted avian influenza H9N2 with the mutation as substitution of E627K in the PB2 protein confirmed the E627K to be responsible for the higher virulence of H5N1 in mice. The mutation PB2-E627K located on the microRNAs binding site responsible for the altered recognition of mmu-mir-1904 may explain why the mutation of PB2-E627K play the key role in virulence to mice . In this study, the increased miR-1902 and miR-1904 of the whole blood could only be found 6 h after LTA treatment; however, using spiked-in cel-miR-39 as an internal control, significant expression of miR-1902 and miR-1904 in the serum may be detectable as early as 2 h following exposure to LTA. We believed this phenomenon is due to the disturbance of measurement by the cellular component of the whole blood as well as the use of U6 snRNA as an internal control, since these up-regulated miRNAs are located in the serum but not in the WBCs and the U6 snRNA is not a good candidate as a normalization control for miRNAs in the serum [21, 22].
In our previous work, in TLR4 receptor knockout mice, five of eight miRNAs (i.e. let-7d, miR-25, miR-92a, miR-103, and miR-107) was significantly lower following exposure to LPS, with unchanged levels of the other three miRNAs . However, in this study, higher expression of miR-451, miR-668, miR-1902, and miR-1904 in the serum were observed in Tlr2−/− against C57BL/6 mice following LTA injection. This observation indicated that these 4 miRNAs were not induced directly by the TLR2 signaling. Because most pathogens can engage multiple TLRs, some authors speculate that those miRNAs induced by TLR singalling may regulate the strength, location, and timing of TLR responses and avoid excess pro-inflammtory repsonses as a negative feedback loop by targeting the TLR signaling molecules and shutting down several TLR pathways . In addition, different expressed miRNAs may work together to control the expression of TLR signal components . Whether the higher expression of miR-451, miR-668, miR-1902, and miR-1904 in the serum upon LTA stimulation is due to lack of the repressed targets of negative feedback loop in Tlr2−/− mice is speculated but lack of evidence so far and required further investigation and validation.
When compared to those upon LPS treatment in our previous work , the circulating miRNA signature after LTA treatment in this study has some additional limitations. First, LPS is a stronger stimulator than LTA to induce the expression of circulating miRNAs, considering the up-regulated 8 miRNAs of the whole blood showed approximately 5- to 12-fold increase in expression 6 h after 100 and 1000 μg LPS injection, these four miRNAs (miR-451, miR-668, miR-1902, and miR-1904) had a less prominent 2- to 6-fold increase upon LTA treatment. LTA has a simpler structure that typically consists of a polyglycerolphosphate (PGP) chain that is linked via a glycolipid anchor to the bacterial membrane . There was a small difference between the chemical structures of PGP-type LTA from different Gram-positive bacteria. For example, additional N-acetylglucosamine modifications of the hydroxyl groups at position C2 of PGP chain are found in B. subtilis but not in the S. aureus. Although LTA is a major immunostimulating component in the cell wall of Gram-positive bacteria, it is expressed on not only pathogenic but also nonpathogenic Gram-positive bacteria. LTAs from Staphylococcus aureus (pathogenic), Bacillus subtilis (non-pathogenic), or Lactobacillus plantarum (beneficial) carry differential potencies in the stimulation of TLR2 and expression of inflammatory cytokines  as well as nitric oxide signaling pathway . In this study, LTA from Bacillus subtilis demonstrated a different expression to those from Streptococcus faecalis and Staphylococcus aureus. However, with a weaker stimulator for miRNA expression, the sensitivity and specificity of complex miRNA expression in diagnosis may be limited. Second, unlike TLR4 comprised by the homogenous dimers, TLR2 is involved in the recognition of a wide range of pathogen-associated molecular patterns (PAMPs) derived from Gram-positive bacteria beside LTA, including bacterial lipoproteins [28, 29], and peptidoglycan , albeit the latter for TLR2 signaling is still an issue of debate . This high versatility of ligand recognition by TLR2 is possibly due to the ability of TLR2 to form heterodimers with TLR1 or TLR6 . Third, LTAs are commonly referred to as membrane-associated polymers characteristic of gram-positive bacteria, just as lipopolysaccharides are believed to be ubiquitous among gram-negative bacteria . However, the number of gram-positive bacteria now known to lack classical LTA is steadily increasing [24, 33], that may limit the use of circulating miRNAs as the biomarkers for exposure to Gram-positive bacteria.
Despite accumulating evidence of miRNAs in the circulation, the origin, the composition, and the function of these circulating extracellular miRNAs remains poorly understood . Although the expression of circulating miRNAs is thought to reflect extrusion of miRNAs from relevant remote tissues or organs or disease processes , currently, little is known regarding the biologic roles of these molecules at distant sites in the body . Three sources of circulating miRNAs had been suggested, including (1) passive leakage from broken cells due to tissue injury, chronic inflammation, cell apoptosis or necrosis, or from cells with a short half-life, such as platelets; (2) active secretion via microvesicles, including exosomes and shedding vesicles; (3) active secretion using a microvesicle-free, RNA-binding protein-dependent pathway, where a significant portion of circulating miRNAs in plasma is associated with high-density lipoprotein (HDL) , Argonaute2 (AGO2) [37, 38], and another RNA-binding protein, nucleophosmin 1 (NPM1) . From this study and our previous work, although we had identified different expression signature of the circulating miRNAs following LPS and LTA exposure as promising biomarkers at the very first step; however, further investigation is required to understand the location of expressed miRNAs in the circulation and to clarify their origins and physiological roles.
A specific circulating miRNA signature was identified in mice exposed to LTA. That expression profile is different from those of mice exposed to LPS. Those circulating miRNAs induced by LTA or LPS treatment may serve as promising biomarkers for the differentiation between exposures to Gram-positive or Gram-negative bacteria.
The work was supported by Chang Gung Memorial Hospital (grant CMRPG 891361 to Ching-Hua Hsieh), Taiwan.
- Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006, 11 (4): 441-450. 10.1016/j.devcel.2006.09.009.View ArticlePubMedGoogle Scholar
- Stefani G, Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008, 9 (3): 219-230. 10.1038/nrm2347.View ArticlePubMedGoogle Scholar
- Perron MP, Boissonneault V, Gobeil LA, Ouellet DL, Provost P: Regulatory RNAs: future perspectives in diagnosis, prognosis, and individualized therapy. Methods Mol Biol. 2007, 361: 311-326.PubMed CentralPubMedGoogle Scholar
- Etheridge A, Lee I, Hood L, Galas D, Wang K: Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011, 717 (1–2): 85-90.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.View ArticlePubMedGoogle Scholar
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008, 105 (30): 10513-10518. 10.1073/pnas.0804549105.PubMed CentralView ArticlePubMedGoogle Scholar
- Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101 (10): 2087-2092. 10.1111/j.1349-7006.2010.01650.x.View ArticlePubMedGoogle Scholar
- Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 2010, 56 (11): 1733-1741. 10.1373/clinchem.2010.147405.View ArticlePubMedGoogle Scholar
- Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N: Serum microRNAs are promising novel biomarkers. PLoS One. 2008, 3 (9): e3148-10.1371/journal.pone.0003148.PubMed CentralView ArticlePubMedGoogle Scholar
- Qu H, Xu W, Huang Y, Yang S: Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011, 12 (5): 1117-1125.PubMedGoogle Scholar
- Gustot T: Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care. 2011, 17 (2): 153-159. 10.1097/MCC.0b013e328344b446.View ArticlePubMedGoogle Scholar
- De Castro C, Parrilli M, Holst O, Molinaro A: Microbe-associated molecular patterns in innate immunity: extraction and chemical analysis of gram-negative bacterial lipopolysaccharides. Methods Enzymol. 2010, 480: 89-115.View ArticlePubMedGoogle Scholar
- Lappin E, Ferguson AJ: Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009, 9 (5): 281-290. 10.1016/S1473-3099(09)70066-0.View ArticlePubMedGoogle Scholar
- Hsieh CH, Rau CS, Jeng JC, Chen YC, Lu TH, Wu CJ, Wu YC, Tzeng SL, Yang JC: Whole blood-derived microRNA signatures in mice exposed to lipopolysaccharides. J Biomed Sci. 2012, 19: 69-10.1186/1423-0127-19-69.PubMed CentralView ArticlePubMedGoogle Scholar
- Podolska A, Anthon C, Bak M, Tommerup N, Skovgaard K, Heegaard PM, Gorodkin J, Cirera S, Fredholm M: Profiling microRNAs in lung tissue from pigs infected with Actinobacillus pleuropneumoniae. BMC Genomics. 2012, 13 (459): 1471-2164.Google Scholar
- Rosenberger CM, Podyminogin RL, Navarro G, Zhao GW, Askovich PS, Weiss MJ, Aderem A: miR-451 regulates dendritic cell cytokine responses to influenza infection. J Immunol. 2012, 189 (12): 5965-5975. 10.4049/jimmunol.1201437.PubMed CentralView ArticlePubMedGoogle Scholar
- Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G: Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011, 6 (9): 1-View ArticleGoogle Scholar
- Yuchuan H, Ya D, Jie Z, Jingqiu C, Yanrong L, Dongliang L, Changguo W, Kuoyan M, Guangneng L, Fang X: Circulating miRNAs might be promising biomarkers to reflect the dynamic pathological changes in smoking-related interstitial fibrosis. Toxicol Ind Health. 2012, 10: 10-Google Scholar
- Al-Quraishy S, Delic D, Sies H, Wunderlich F, Abdel-Baki AA, Dkhil MA: Differential miRNA expression in the mouse jejunum during garlic treatment of Eimeria papillata infections. Parasitol Res. 2011, 109 (2): 387-394. 10.1007/s00436-011-2266-y.View ArticlePubMedGoogle Scholar
- Zhang Z, Hu S, Li Z, Wang X, Liu M, Guo Z, Li S, Xiao Y, Bi D, Jin H: Multiple amino acid substitutions involved in enhanced pathogenicity of LPAI H9N2 in mice. Infect Genet Evol. 2011, 11 (7): 1790-1797. 10.1016/j.meegid.2011.07.025.View ArticlePubMedGoogle Scholar
- Li Y, Kowdley KV: Method for microRNA isolation from clinical serum samples. Anal Biochem. 2012, 11 (12): 007-Google Scholar
- Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z: Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012, 57 (4): 897-904. 10.1007/s10620-011-1981-7.View ArticlePubMedGoogle Scholar
- O'Neill LA, Sheedy FJ, McCoy CE: MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol. 2011, 11 (3): 163-175. 10.1038/nri2957.View ArticlePubMedGoogle Scholar
- Reichmann NT, Grundling A: Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes. FEMS Microbiol Lett. 2011, 319 (2): 97-105. 10.1111/j.1574-6968.2011.02260.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Fischer W: Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med Microbiol Immunol. 1994, 183 (2): 61-76. 10.1007/BF00277157.View ArticlePubMedGoogle Scholar
- Ryu YH, Baik JE, Yang JS, Kang SS, Im J, Yun CH, Kim DW, Lee K, Chung DK, Ju HR: Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids. Int Immunopharmacol. 2009, 9 (1): 127-133. 10.1016/j.intimp.2008.10.014.View ArticlePubMedGoogle Scholar
- Zidek Z, Farghali H, Kmonickova E: Intrinsic nitric oxide-stimulatory activity of lipoteichoic acids from different Gram-positive bacteria. Nitric Oxide. 2010, 23 (4): 300-310. 10.1016/j.niox.2010.09.001.View ArticlePubMedGoogle Scholar
- Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, Krikae F, Kirikae T, Gotz F: Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol. 2006, 177 (5): 3162-3169.View ArticlePubMedGoogle Scholar
- Hashimoto M, Furuyashiki M, Kaseya R, Fukada Y, Akimaru M, Aoyama K, Okuno T, Tamura T, Kirikae T, Kirikae F: Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect Immun. 2007, 75 (4): 1926-1932. 10.1128/IAI.02083-05.PubMed CentralView ArticlePubMedGoogle Scholar
- Dziarski R, Gupta D: The peptidoglycan recognition proteins (PGRPs). Genome Biol. 2006, 7 (8): 232-10.1186/gb-2006-7-8-232.PubMed CentralView ArticlePubMedGoogle Scholar
- Pietrocola G, Arciola CR, Rindi S, Di Poto A, Missineo A, Montanaro L, Speziale P: Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus. Int J Artif Organs. 2011, 34 (9): 799-810. 10.5301/ijao.5000030.View ArticlePubMedGoogle Scholar
- Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K: Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006, 281 (41): 31002-31011. 10.1074/jbc.M602794200.View ArticlePubMedGoogle Scholar
- Sutcliffe IC, Shaw N: Atypical lipoteichoic acids of gram-positive bacteria. J Bacteriol. 1991, 173 (22): 7065-7069.PubMed CentralPubMedGoogle Scholar
- Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011, 8 (8): 467-477. 10.1038/nrclinonc.2011.76.PubMed CentralView ArticlePubMedGoogle Scholar
- Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009, 9 (6): 703-711. 10.1517/14712590902932889.View ArticlePubMedGoogle Scholar
- Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011, 13 (4): 423-433. 10.1038/ncb2210.PubMed CentralView ArticlePubMedGoogle Scholar
- Turchinovich A, Weiz L, Langheinz A, Burwinkel B: Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39 (16): 7223-7233. 10.1093/nar/gkr254.PubMed CentralView ArticlePubMedGoogle Scholar
- Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011, 108 (12): 5003-5008. 10.1073/pnas.1019055108.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang K, Zhang S, Weber J, Baxter D, Galas DJ: Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010, 38 (20): 7248-7259. 10.1093/nar/gkq601.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.